TLDR; The Value of Drugs for Rare Disease Indications May Be Higher Than You Think – Assets for Neurodevelopmental Disorders Alone May Be Worth Beyond USD $420B.
Enlightenbio Releases New Report: Warehousing Clinical & Genomics Biomedical Data – A Needs & Challenges Analysis Report
Seven Bridges Announces Initial Close of Series C Funding from New Strategic Investor to Accelerate Product Development and Commercial Growth
QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute
Seven Bridges Advances Workflow Automation Capabilities to Make Complex Multi-Omic Analysis More Accessible to Broader Mix of Users